Genetic cancer risk and behavioral search patterns: what BRCA searches tell us
BRCA-related searches spike predictably around celebrity disclosures and awareness months, but the behavioral patterns underneath reveal far more than public interest. Genetic cancer risk data, when mapped against search timing, query specificity, and geographic clustering, exposes populations in active decision-making who never appear in clinical data systems. VIOLET tracks these behavioral signals to identify underserved hereditary cancer populations before they reach a genetic counselor.
Every month, approximately 450,000 people in the United States search for BRCA-related terms. Most of them will never appear in a clinical data system. They are searching from phones at 11 p.m., comparing genetic testing costs, reading about Angelina Jolie's decision, and trying to determine whether their family history warrants action. This pre-clinical behavioral layer contains population-level intelligence that traditional healthcare data pipelines miss entirely.
The top-ranking pages for BRCA queries explain what the genes do. They define risk. They list cancer types. None of them analyze what the search behavior itself reveals about unmet need, geographic disparity, or the gap between awareness and clinical engagement. That gap is where hereditary cancer behavioral intelligence starts.
What BRCA genetic testing actually shows
BRCA genetic testing identifies harmful variants (previously called mutations) in the BRCA1 and BRCA2 genes. These genes produce tumor suppressor proteins. When either gene carries a pathogenic variant, the proteins do not function correctly, and cells are more likely to develop into cancer.
A positive result does not mean a person has cancer. It means their lifetime risk of developing certain cancers is significantly elevated. For BRCA1 carriers, the lifetime breast cancer risk reaches 55% to 72%. For BRCA2 carriers, it ranges from 45% to 69%. Ovarian cancer risk runs 39% to 44% for BRCA1 and 11% to 17% for BRCA2.
But here is what the clinical definitions miss: people searching "what does BRCA testing show" are often two to six months away from requesting a test. They are in an information-gathering phase that has no clinical record, no chart note, no billing code. VIOLET maps this phase.
The Angelina Jolie effect and what it reveals about search cascades
Is Angelina Jolie a BRCA1 or BRCA2 carrier? She carries a BRCA1 pathogenic variant and disclosed it publicly in a 2013 New York Times op-ed. Her disclosure triggered a measurable and well-documented phenomenon: BRCA-related searches increased by 64% in the two weeks following publication, and referrals for genetic testing rose by 37% in the following months.
This "Jolie effect" recurs at smaller scale during Breast Cancer Awareness Month, after celebrity disclosures, and following news coverage of genetic testing companies. The pattern matters because it creates temporal windows where large populations are actively considering hereditary cancer risk. Identifying those windows, their geographic concentration, and the query specificity within them gives pharma companies, health systems, and payers a real-time map of population-level intent.
Which cancers matter most for BRCA1 and BRCA2
The most common cancer associated with BRCA2 is breast cancer, with lifetime risk approaching 69%. BRCA2 also carries elevated risk for ovarian, pancreatic, prostate, and melanoma cancers. BRCA1 is most strongly associated with breast and ovarian cancers, with ovarian cancer risk notably higher than BRCA2.
Which is more serious, BRCA1 or BRCA2? Neither is categorically "more serious." BRCA1 carries a higher ovarian cancer risk. BRCA2 is associated with a broader range of cancer types, including prostate and pancreatic. The clinical significance depends on sex, family history, and co-occurring risk factors. But in search data, "which is worse BRCA1 or BRCA2" is one of the highest-volume comparison queries, signaling that people are trying to make personal risk assessments without clinical guidance.
What search behavior tells us that clinical data cannot
Search queries for "BRCA gene testing cost" and "who should get BRCA testing" reveal populations evaluating access barriers. When these queries cluster in specific ZIP codes, particularly in rural or underserved areas, they indicate populations with hereditary cancer risk awareness but limited clinical access.
Searches for "BRCA gene in men" have increased 28% year-over-year, reflecting growing awareness that BRCA variants are not sex-limited. Male BRCA2 carriers face a lifetime prostate cancer risk of up to 34% and a breast cancer risk of approximately 7%. Yet male BRCA carrier identification remains far below expected prevalence. The search signal is ahead of the clinical system.
VIOLET processes these behavioral patterns across millions of queries, mapping them to geographic, demographic, and temporal dimensions. The result is not a keyword report. It is a population-level behavioral intelligence layer that identifies hereditary cancer risk populations before they enter any clinical workflow.
Key statistics
Why genetic cancer risk data needs a trust layer
Genetic cancer risk data flows through labs, genetic counselors, EHR systems, direct-to-consumer platforms, and patient portals. Each handoff introduces provenance questions. Was consent properly captured for secondary use? How recent is the variant classification? Does the record match across systems?
SuperTruth's Data Trust Index scores every health data record from 0 to 100 across eight dimensions: Provenance (25%), Consent (20%), Recency (15%), Quality (10%), Concordance (10%), Validation (10%), Breadth (5%), and Stability (5%). For genetic cancer risk data specifically, Provenance and Consent carry outsized importance. A BRCA test result that cannot demonstrate chain of custody or valid consent for AI training is not just low-quality. It is a liability.
When behavioral intelligence from VIOLET combines with trust-scored genetic data from the DTI Engine, the result is a complete picture: who is searching, what they are searching for, where access gaps exist, and whether the underlying data is trustworthy enough to act on.
From search signal to clinical action
The current system waits for patients to arrive at a genetic counselor's office. By that point, months or years of behavioral signal have gone unrecorded. Health systems that integrate hereditary cancer behavioral intelligence can intervene earlier, direct outreach to high-intent populations, and close the gap between awareness and testing.
Pharma companies launching BRCA-related therapies can use this intelligence to identify geographic clusters of undiagnosed carriers. Payers can map where genetic testing utilization falls below expected prevalence. Researchers can identify underrepresented populations for clinical trial recruitment.
The data is already there. It just needs to be scored, structured, and made actionable.
To explore how VIOLET maps hereditary cancer behavioral intelligence for your population, contact Louis Simeonidis, SVP Commercial Operations, at louis@supertruth.ai or (215) 918-4140.
Further reading:
Jason Alan Snyder
Co-founder of SuperTruth and Artists & Robots, and an inventor on the Data Trust Index patents. Twenty-plus years building technology inside Interpublic Group. He writes here nearly every day on data trust, provenance, and what AI should be allowed to act on, and publishes essays on his Substack.
About SuperTruth · LinkedIn · Substack · jasonalansnyder.com
See it in practice
750+ cancer search terms. Live in production.
VIOLET maps behavioral signals 12–18 months before clinical presentation.